• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by AstraZeneca PLC

    8/28/25 11:14:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email
    6-K 1 a0720x.htm HOLDING(S) IN COMPANY a0720x
    FORM 6-K
     
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    Report of Foreign Issuer
     
    Pursuant to Rule 13a-16 or 15d-16 of
    the Securities Exchange Act of 1934
     
    For the month of August 2025
     
    Commission File Number: 001-11960
     
    AstraZeneca PLC
     
    1 Francis Crick Avenue
    Cambridge Biomedical Campus
    Cambridge CB2 0AA
    United Kingdom
     
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
     
    Form 20-F X Form 40-F __
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
     
    Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
     
    Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
     
    Yes __ No X
     
    If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________
     
     
     
     
    AstraZeneca PLC
     
    INDEX TO EXHIBITS
     
     
    1.
    Holding(s) in Company
     
    28 August 2025
     
    On 27 August 2025, AstraZeneca PLC (the Company) was notified by The Capital Group Companies, Inc. (Capital Group) that the TR-1 notification it submitted to the Company on 25 August 2025, and which was subsequently announced by the Company on 26 August 2025, was provided in error.
     
    Accordingly, shareholders should disregard the TR-1 notification announced by the Company on 26 August 2025 and instead refer to the TR-1 notification in relation to Capital Group announced by the Company on 21 August 2025, which is available under RNS No. 2435W / at:
    https://otp.tools.investis.com/clients/uk/astrazeneca/rns/regulatory-story.aspx?cid=1343&newsid=1979582&culture=en-GB&val=638918832221613810
     
    AstraZeneca 
    AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca 
     
    Contacts
    For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here.
     
    Matthew Bowden
    Company Secretary
    AstraZeneca PLC
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
     
    AstraZeneca PLC
     
     
    Date: 28 August 2025
     
     
    By: /s/ Matthew Bowden
     
    Name: Matthew Bowden
     
    Title: Company Secretary
    Get the next $AZN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial

    Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

    8/30/25 10:19:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FLUMIST (Influenza, Vaccine Live, Intranasal), the nation's only nasal spray flu vaccine, now available for home delivery

    AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination AstraZeneca today launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST® (Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250815310613/en/ Initially approved by the Food and Drug Admin

    8/15/25 8:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Healthcare Businesswomen's Association (HBA) Honors AstraZeneca and Viseven with 2025 ACE Awards for Workforce Innovation and Global Impact

    The HBA's ACE Awards spotlight bold, people-first programs that are transforming how the industry develops, engages, and empowers its workforce. FAIRFIELD, N.J., Aug. 13, 2025 /PRNewswire/ -- The Healthcare Businesswomen's Association (HBA) today announced the recipients of its 2025 Advancement, Commitment, and Engagement (ACE) Awards, honoring high-impact programs that are redefining workforce development across the healthcare industry. The ACE Awards recognize standout programs with bold strategies that prioritize people, scale globally, deliver measurable business and social outcomes, and honor the future of leadership and innovation in healthcare. This year's honorees include:

    8/13/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

    Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

    4/15/25 12:40:56 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca upgraded by UBS

    UBS upgraded AstraZeneca from Neutral to Buy

    2/13/25 8:39:12 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on AstraZeneca

    Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

    2/12/25 6:59:42 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Financials

    Live finance-specific insights

    View All

    Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial

    Baxdrostat 2mg lowered systolic blood pressure by 15.7 mmHg (9.8 mmHg placebo-adjusted) from baseline, and was generally well tolerated with no unanticipated safety findings Full results presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine Positive full results from the ​BaxHTN Phase III trial showed ​baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top

    8/30/25 10:19:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AstraZeneca results: H1 and Q2 2025

    Strong growth momentum continues with excellent R&D pipeline delivery in the year-to-date AstraZeneca: Revenue and EPS summary   H1 2025 % Change Q2 2025 % Change   $m Actual CER1 $m Actual CER - Product Sales 26,670 8 10 13,795 11 10 - Alliance Revenue 1,293 38 38 654 36 35 Product Revenue2 27,963 9 11 14,449 12 11 Collaboration Revenue 82 68 66 8 >2x >2x Total Revenue 28,045 9 11 14,457 12 11

    7/29/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial in patients with uncontrolled or treatment resistant hypertension

    Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo Positive high-level results from the BaxHTN Phase III trial showed baxdrostat at two doses (2mg and 1mg) demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) compared with placebo at 12 weeks. The trial also successfully met all secondary endpoints. Patients with uncontrolled or treatment resistant hypertension received baxdrostat or placebo on top of standard of care. Baxdrostat was generally well tolerated with a favorable safety profile. There are 1.3 billion people worldwide livin

    7/14/25 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/4/22 9:06:48 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

    2/3/21 1:13:21 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    SEC Filings

    View All

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/28/25 11:14:38 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/26/25 1:22:13 PM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by AstraZeneca PLC

    6-K - ASTRAZENECA PLC (0000901832) (Filer)

    8/21/25 10:51:20 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    View All

    I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

    ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

    6/6/24 7:00:00 AM ET
    $AZN
    $IMAB
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

    In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

    2/26/24 9:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

    NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

    10/18/23 9:00:00 AM ET
    $AZN
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care